ANTERIS TECHNOLOGIES GLOBAL Stock Price, News & Analysis

Anteris Technologies (NASDAQ: AVR) announced on October 27, 2025 that the first patients were enrolled and successfully treated in the global pivotal PARADIGM Trial evaluating the DurAVR® Transcatheter Heart Valve (THV) for severe calcific aortic stenosis.

The initial procedures were performed at Rigshospitalet, Copenhagen by Prof. Dr. Ole De Backer. The head-to-head study will randomize patients across surgical risk groups and builds on an existing clinical dataset of 130 patients previously treated with DurAVR® (including de novo, valve-in-valve, and bicuspid anatomies). Anteris plans near-term expansion of PARADIGM into the United States, Europe and Canada to accelerate enrollment and evidence generation toward commercialization.

Anteris Technologies (NASDAQ: AVR) announced that one-year clinical outcomes for the DurAVR® Transcatheter Heart Valve (THV) will be presented at TCT 2025 on October 27, 2025 at 2:27pm GMT-7 in the Innovation Theater, Moscone Center, San Francisco.

The oral presentation, titled “The DurAVR® Biomimetic TAVR System in Patients with Small Aortic Annuli (Anteris): One-Year Clinical and Hemodynamic Outcomes,” summarizes outcomes in over 100 patients with symptomatic severe aortic stenosis and small aortic annuli (annulus area 396 ± 37 mm2). The company said the outcomes to date are encouraging and will be further evaluated in the global pivotal PARADIGM Trial, a prospective randomized controlled trial comparing DurAVR THV to commercially available TAVRs for safety and effectiveness.

Anteris (NASDAQ: AVR) received regulatory clearance from the Danish Medicines Agency to start the global pivotal PARADIGM Trial of the DurAVR® transcatheter heart valve for severe calcific aortic stenosis, announced on October 15, 2025.

Patient recruitment at Danish centers is expected to begin in 4Q 2025, with planned expansion across the United States, Europe and Canada. An IDE remains under review by the U.S. FDA, and U.S. sites will begin once IDE and IRB approvals are obtained. Management cites trial design aimed to support future PMA and CE Mark approvals.

Anteris Technologies Global Corp. (NASDAQ: AVR) announced the adjournment of its Special Meeting of Stockholders due to lack of required quorum. The meeting has been rescheduled for September 29, 2025, at 8:00 a.m. Central time.

The virtual meeting will be held via webcast, maintaining the original record date of August 11, 2025. Stockholders who haven't voted can still do so, with proxy submissions due by September 28, 2025, at 11:59 p.m. Eastern time for online/telephone votes, and September 26, 2025 for mail-in proxies. CDI holders must submit voting instructions by September 25, 2025, at 5:00 p.m. Central time.

Anteris Technologies Global Corp. (NASDAQ: AVR) has announced the postponement of its Special Meeting of Stockholders from September 11 to September 18, 2025. The virtual meeting will be held at 5:00 p.m. Central time via live webcast.

The postponement aims to provide stockholders additional time to vote on proposals outlined in the Company's August 18 Proxy Statement. The record date remains August 11, 2025. Previously cast votes will remain valid unless changed. The Board unanimously recommends voting FOR the proposals.

Stockholders can vote via Internet or telephone until September 17, while CDI holders must submit their Voting Instruction Forms by September 16. All relevant materials are available on the SEC website and the company's investor relations page.

Anteris Technologies Global Corp. (NASDAQ: AVR) has announced the postponement of its Special Meeting of Stockholders from September 4, 2025, to September 11, 2025, at 5:00 p.m. Central time. The meeting will be held virtually via webcast at www.virtualshareholdermeeting.com/AVR2025SM.

The Record Date remains unchanged at August 11, 2025. The postponement aims to provide stockholders additional time to vote on the proposals outlined in the Company's Proxy Statement filed on August 18, 2025. The Board of Directors unanimously recommends voting FOR all proposals.

Previously cast votes will remain valid unless changed. Stockholders can submit new votes via Internet or telephone by September 10, 2025, while CDI holders must submit voting instructions by September 9, 2025.

Anteris Technologies (NASDAQ: AVR) has reported its Q2 2025 financial results and corporate updates, highlighting significant progress in its DurAVR® THV (transcatheter heart valve) program. The company has successfully treated 130 patients with DurAVR® since clinical development began, including 21 patients in Q2 2025.

Key developments include the world's first "double DurAVR®" implant for both mitral and aortic valve positions, and advancement of the global PARADIGM Trial with 79 qualified clinical sites. The company appointed Dr. Michael J. Reardon and Professor Stephan Windecker as Trial Co-Chairs and added two new board members. Financial results show net operating cash outflows of $41.0 million for H1 2025, with $28.4 million in cash as of June 30, 2025.

Anteris Technologies Global Corp. (NASDAQ/ASX: AVR) has appointed David Roberts and Gregory Moss to its Board of Directors, while Dr. Wenyi Gu has resigned. Roberts, currently President of LeMaitre Vascular (NASDAQ: LMAT) since 2007, brings extensive healthcare executive experience and financial expertise. Moss serves as Chief Business and Legal Officer at Evommune and previously led Kadmon's $1.9B acquisition by Sanofi. These U.S.-based appointments follow Anteris' Q4 2024 NASDAQ listing and come as the company prepares to launch its DurAVR® THV global pivotal clinical trial (PARADIGM Trial) in Q3 2025. The strategic board changes aim to strengthen Anteris' leadership as it pursues U.S. and EMA licensure for its DurAVR® THV treatment for aortic stenosis patients.

Anteris Technologies (NASDAQ: AVR) reported Q1 2025 financial results and corporate updates. Key highlights include the submission of an IDE application for the DurAVR® THV's PARADIGM Trial to FDA, achievement of treating 100 patients with DurAVR® THV, and expansion of manufacturing capacity. The company reported net sales of $0.6M (down 27% YoY) and a net loss of $21.9M (increased 36% YoY). R&D expenses increased 42% to $16.5M due to manufacturing scale-up and trial preparations. One-year clinical data showed favorable hemodynamics with an Effective Orifice Area of 2.1cm², Mean Pressure Gradient of 8.6 mmHg, and no valve-related mortality. The company ended Q1 with $49.0M in cash and was included in the FTSE Russell 2000® Index.